Kymab Limited   Report issue

For profit Phase 2
Founded: Cambridge United Kingdom (2010)
Status: Acquired by Sanofi-Aventis (2021)

Organization Overview

First Clinical Trial
2017
NCT03161288
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kymab Limited | Kymab Ltd